Puja Mehta1, Sebastian E Sattui2, Kornelis S M van der Geest3, Elisabeth Brouwer3, Richard Conway4, Michael S Putman5, Philip C Robinson6, Sarah L Mackie7. 1. P. Mehta, Rheumatology Fellow, MD, Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, Department of Rheumatology, University College London Hospital (UCLH) NHS Trust, London, UK. 2. S.E. Sattui, Rheumatology Fellow, MD, Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA. 3. K. van der Geest, Rheumatology Fellow, PhD, E. Brouwer, Internist Rheumatologist, Associate Professor, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 4. R. Conway, Consultant Rheumatologist, PhD, Department of Rheumatology, St. James's Hospital, Dublin, Ireland. 5. M.S. Putman, Clinical Instructor of Medicine, MD, Division of Rheumatology, Department of Medicine, Northwestern University, Chicago, IL, USA. 6. P. Robinson, Associate Professor, PhD, University of Queensland Faculty of Medicine, Brisbane, Australia. 7. S.L. Mackie, Associate Clinical Professor and Honorary Consultant Rheumatologist, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK. s.l.mackie@leeds.ac.uk.
Abstract
OBJECTIVE: To identify shared and distinct features of giant cell arteritis (GCA) and coronavirus disease 2019(COVID-19) to reduce diagnostic errors that could cause delays in correct treatment. METHODS: Two systematic literature reviews determined the frequency of clinical features of GCA and COVID-19 in published reports. Frequencies in each disease were summarized using medians and ranges. RESULTS: Headache was common in GCA but was also observed in COVID-19 (GCA 66%, COVID-19 10%). Jaw claudication or visual loss (43% and 26% in GCA, respectively) generally were not reported in COVID-19. Both diseases featured fatigue (GCA 38%, COVID-19 43%) and elevated inflammatory markers (C-reactive protein [CRP] elevated in 100% of GCA, 66% of COVID-19), but platelet count was elevated in 47% of GCA but only 4% of COVID-19 cases. Cough and fever were commonly reported in COVID-19 and less frequently in GCA (cough, 63% for COVID-19 vs 12% for GCA; fever, 83% for COVID-19 vs 27% for GCA). Gastrointestinal upset was occasionally reported in COVID-19 (8%), rarely in GCA (4%). Lymphopenia was more common in COVID-19 than GCA (53% in COVID-19, 2% in GCA). Alteration of smell and taste have been described in GCA but their frequency is unclear. CONCLUSION: Overlapping features of GCA and COVID-19 include headache, fever, elevated CRP and cough. Jaw claudication, visual loss, platelet count and lymphocyte count may be more discriminatory. Physicians should be aware of the possibility of diagnostic confusion. We have designed a simple checklist to aid evidence-based evaluation of patients with suspected GCA.
OBJECTIVE: To identify shared and distinct features of giant cell arteritis (GCA) and coronavirus disease 2019(COVID-19) to reduce diagnostic errors that could cause delays in correct treatment. METHODS: Two systematic literature reviews determined the frequency of clinical features of GCA and COVID-19 in published reports. Frequencies in each disease were summarized using medians and ranges. RESULTS: Headache was common in GCA but was also observed in COVID-19 (GCA 66%, COVID-19 10%). Jaw claudication or visual loss (43% and 26% in GCA, respectively) generally were not reported in COVID-19. Both diseases featured fatigue (GCA 38%, COVID-19 43%) and elevated inflammatory markers (C-reactive protein [CRP] elevated in 100% of GCA, 66% of COVID-19), but platelet count was elevated in 47% of GCA but only 4% of COVID-19 cases. Cough and fever were commonly reported in COVID-19 and less frequently in GCA (cough, 63% for COVID-19 vs 12% for GCA; fever, 83% for COVID-19 vs 27% for GCA). Gastrointestinal upset was occasionally reported in COVID-19 (8%), rarely in GCA (4%). Lymphopenia was more common in COVID-19 than GCA (53% in COVID-19, 2% in GCA). Alteration of smell and taste have been described in GCA but their frequency is unclear. CONCLUSION: Overlapping features of GCA and COVID-19 include headache, fever, elevated CRP and cough. Jaw claudication, visual loss, platelet count and lymphocyte count may be more discriminatory. Physicians should be aware of the possibility of diagnostic confusion. We have designed a simple checklist to aid evidence-based evaluation of patients with suspected GCA.
Authors: Lai-Shan Tam; Yoshiya Tanaka; Rohini Handa; Zhanguo Li; Jose Paulo Lorenzo; Worawit Louthrenoo; Catherine Hill; Kevin Pile; Philip C Robinson; Leonila F Dans; Li Yang Hsu; Sang-Min Lee; Jiacai Cho; A T M Tanveer Hasan; Babur Salim; Saba Samreen; Syahrul Sazliyana Shaharir; Priscilla Wong; Jeffrey Chau; Debashish Danda; Syed Atiqul Haq Journal: Int J Rheum Dis Date: 2021-05-04 Impact factor: 2.454
Authors: Sarah L Mackie; Elisabeth Brouwer; Richard Conway; Kornelis S M van der Geest; Puja Mehta; Susan P Mollan; Lorna Neill; Michael Putman; Philip C Robinson; Sebastian E Sattui Journal: Lancet Rheumatol Date: 2020-12-08
Authors: Urszula Szydełko-Paśko; Joanna Przeździecka-Dołyk; Julia Kręcicka; Rafał Małecki; Marta Misiuk-Hojło; Anna Turno-Kręcicka Journal: Am J Case Rep Date: 2022-01-11
Authors: Yannick van Sleen; Philip Therkildsen; Berit Dalsgaard Nielsen; Kornelis S M van der Geest; Ib Hansen; Peter Heeringa; Marcel D Posthumus; Maria Sandovici; Erik J M Toonen; Jannik Zijlstra; Annemieke M H Boots; Ellen-Margrethe Hauge; Elisabeth Brouwer Journal: Arthritis Res Ther Date: 2022-03-07 Impact factor: 5.156